Recursion Pharmaceuticals
RXRX
267 hedge funds and large institutions have $1.74B invested in Recursion Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 112 increasing their positions, 52 reducing their positions, and 45 closing their positions.
115% more repeat investments, than reductions
Existing positions increased: 112 | Existing positions reduced: 52
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
2% less first-time investments, than exits
New positions opened: 44 | Existing positions closed: 45
1% less funds holding
Funds holding: 270 → 267 (-3)
8% less capital invested
Capital invested by funds: $1.89B → $1.74B (-$145M)
15.24% less ownership
Funds ownership: 109.46% → 94.22% (-15%)
42% less call options, than puts
Call options by funds: $11.4M | Put options by funds: $19.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$33.2M |
| 2 |
State Street
Boston,
Massachusetts
|
+$29.5M |
| 3 |
BlackRock
New York
|
+$24.6M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$19.5M |
| 5 |
DM
Deerfield Management
New York
|
+$16.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Laurion Capital Management
New York
|
-$21.8M |
| 2 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$9.68M |
| 3 |
GCM
Ghisallo Capital Management
Boston,
Massachusetts
|
-$8.25M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$6.09M |
| 5 |
PA
Perceptive Advisors
New York
|
-$5.77M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
IC
301
Innealta Capital
Austin,
Texas
| – | -$1.66K | -221 | Closed |
|
302
National Bank of Canada
Montreal,
Quebec, Canada
| – | -$1.49K | -200 | Closed |
|
|
TWP
303
Triad Wealth Partners
Lawrence,
Kansas
| – | -$1.15K | -153 | Closed |
|
|
QL
304
Quarry LP
New York
| – | -$1.03K | -138 | Closed |
|
|
CA
305
Clearstead Advisors
Cleveland,
Ohio
| – | -$896 | -125 | Closed |
|
|
FFO
306
Fortitude Family Office
Scottsdale,
Arizona
| – | -$608 | -81 | Closed |
|
|
EWA
307
EverSource Wealth Advisors
Birmingham,
Alabama
| – | -$525 | -64 | Closed |
|
|
GI
308
Gradient Investments
Arden Hills,
Minnesota
| – | -$113 | -15 | Closed |
|
|
C
309
Covestor
London,
United Kingdom
| – | -$7 | -1 | -8% |
|
|
CMP
310
Coston McIsaac & Partners
Bar Harbor,
Maine
| – | +$100 | +14 | New |
|
|
RBC
311
Roble Belko & Company
Sewickley,
Pennsylvania
| – | +$115 | +16 | New |
|
RXRX Hedge Fund Activity: Q3 2024 in Review
267 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q3 2024, worth a combined $1.74B — down 7.7% from $1.89B a quarter earlier.
Sellers outnumbered buyers: 45 funds closed out of RXRX and 44 opened new positions — a net loss of 1 holder — while 52 trimmed existing stakes and 112 added.
The largest buyer was ARK Investment Management, adding an estimated $33.2M. The largest seller was Laurion Capital Management, exiting entirely with an estimated $21.8M sold.
- 267 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q3 2024, down from 270 in Q2 2024.
- Funds reported $1.74B of Recursion Pharmaceuticals stock for Q3 2024, down 7.7% quarter-over-quarter.
- 44 funds opened new Recursion Pharmaceuticals positions in Q3 2024 and 45 closed out, a net change of -1 holder.
- The largest Recursion Pharmaceuticals buyer in Q3 2024 was ARK Investment Management, an estimated $33.2M added.
- The largest Recursion Pharmaceuticals seller in Q3 2024 was Laurion Capital Management, an estimated $21.8M sold.
Based on aggregated 13F filings for Q3 2024.